Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Key facts

Sponsor

Vertex Pharmaceuticals Incorporated

Intervention

VX-828(drug)

Enrollment

255 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (12)

• Joe DiMaggio Cycstic Fibrosis & Pulmonary Center, Hollywood, Florida, United States
• AdventHealth Medical Group Pulmonology at Orlando Ridgewood, Orlando, Florida, United States
• Altasciences Clinical Kansas, Overland Park, Kansas, United States
• Kentucky Children's Hospital, Lexington, Kentucky, United States
• Boston Children's Hospital, Boston, Massachusetts, United States
• University of Minnesota -Pulmonology, Minneapolis, Minnesota, United States
• Billings Clinic, Pediatric Pulmonary Dept., Billings, Montana, United States
• New York Medical College, Hawthorne, New York, United States
• ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC, Toledo, Ohio, United States
• Cook Children's Pulmonology, Fort Worth, Texas, United States
• University of Utah Hospital - Pulmonology, Salt Lake City, Utah, United States
• Vermont Lung Center, Colchester, Vermont, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Genetic digestive tract malformation

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06507956
  Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis
  Hospices Civils de Lyon
• RECRUITINGNCT06296394
  Health Outcomes of Parents With Cystic Fibrosis-Aim 2
  University of Pittsburgh
• RECRUITINGNCT06191640
  Sinus Disease in Young Children With Cystic Fibrosis
  University of California, Los Angeles
• RECRUITINGNCT05501587
  Measures of Respiratory Health Registry
  University of British Columbia

See all trials for Genetic digestive tract malformation →